Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 21, Issue 9, 2011, Pages 672-678

  Shimada, K ^a   Murayama, T ^a   Yokode, M ^a   Kita, T ^a   Fujita, M ^a   Kishimoto, C ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Angiotensin II type 1 receptor antagonist; Atherosclerosis; Cytokines; Oxidative stress

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CXCL2 CHEMOKINE; GAMMA INTERFERON; IMIDAZOLE DERIVATIVE; OLMESARTAN; SUPEROXIDE; TETRAZOLE DERIVATIVE; THIOREDOXIN;

ANIMAL; ANIMAL MODEL; AORTA; ARTICLE; ATHEROSCLEROSIS; BLOOD; C57BL MOUSE; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; MALE; METABOLISM; MOUSE; OXIDATIVE STRESS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CELLS, CULTURED; CHEMOKINE CXCL2; IMIDAZOLES; INTERFERON-GAMMA; MALE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; OXIDATIVE STRESS; SUPEROXIDES; TETRAZOLES; THIOREDOXINS;

ANIMALIA; MUS;

EID: 80052765008     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2009.12.016     Document Type: Article

References (40)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999, 340:115-126.
2. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001, 103:904-912.
3. Mollnau H., Wendt M., Szöcs K., Lassègue B., Schulz E., Oelze M., et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002, 90:e58-e65.
4. Warnholtz A., Nickenig G., Schulz E., Macharzina R., Bräsen J.H., Skatchkov M., et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis. Evidence for involvement of the renin-angiotensin system. Circulation 1999, 99:2027-2033.
5. Yuan Z., Nimata M., Okabe T.A., Shioji K., Hasegawa K., Kita T., et al. Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure. Am J Physiol Heart Circ Physiol 2005, 289:H 1147-H 1152.
6. Weinstock J.V., Blum A.M., Kassab J.T. Angiotensin II is chemotactic, for a T-cell subset which can express migration factor activity in murine Schistosomiasis mansoni. Cell Immunol 1987, 107:180-187.
7. Takaya T., Kawashima S., Shinohara M., Yamashita T., Toh R., Sasaki N., et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis 2006, 186:402-410.
8. van der Hoorn J.M., Kleemann R., Havekes L.M., Kooistra T., Princen H.M., Jukema J.W. Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3 Leiden transgenic mice. J Hypertens 2007, 25:2454-2462.
9. Arishiro K., Hoshiga M., Negoro N., Jin D., Takai S., Miyazaki M., et al. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol 2007, 49:1482-1489.
10. Kurata A., Nishizawa H., Kihara S., Maeda N., Sonoda M., Okada T., et al. Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006, 70:1717-1724.
11. Takai S., Jin D., Sakaguchi M., Muramatsu M., Miyazaki M. The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet. J Hypertens 2005, 23:1879-1886.
12. Suzuki J., Iwai M., Li Z., Li J.M., Min L.J., Ide A., et al. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice. J Hypertens 2005, 23:1383-1389.
13. Ferrario C.M. Use of angiotensin II receptor blockers in animal models of atherosclerosis. Am J Hypertens 2002, 15:9S-13S.
14. Plump A.S., Smith J.D., Hayek T., Aalto-Setälä K., Walsh A., Verstuyft J.G., et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992, 71:343-353.
15. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994, 14:133-140.
16. Kato M., Sada T., Chuma H., Mizuno M., Terashima H., Fukushima Y., et al. Severity of hyperlipidemia does not affect antiatherosclerotic effect of an angiotensin II receptor antagonist apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2006, 47:764-769.
17. Murayama T., Yokode M., Kataoka H., Imabayashi T., Yoshida H., Sano H., et al. Intraperitoneal administration of anti-c-fms monoclonal antibody prevents initial events of atherogenesis but does not reduce the size of advanced lesions in apolipoprotein E-deficient mice. Circulation 1999, 99:1740-1746.
18. Okabe T., Kishimoto C., Shimada K., Murayama T., Yokode M., Kita T. Effects of MCI-186 (Edaravone), a novel free radical scavenger, upon experimental atherosclerosis in apolipoprotein E-deficient mice. Circ J 2006, 70:1216-1219.
19. Mizuno M., Sada T., Ikeda M., Fukuda N., Miyamoto M., Yanagisawa H., et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995, 285:181-188.
20. Miller F.J., GuHerman D.D., Rios C.D., Heistad D.D., Davidson B.L. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 1998, 82:1298-1305.
21. Shimada K., Murayama T., Yokode M., Kita T., Uzui H., Ueda T., et al. N-acetylcysteine reduces the severity of atherosclerosis in apolipoprotein E deficient mice via reducing superoxide production. Circ J 2008, 73:1337-1341.
22. Shioji K., Kishimoto C., Nakamura H., Masutani H., Yuan Z., Oka S., et al. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 2002, 106:1403-1409.
23. Miyamoto M., Kishimoto C., Shioji K., Nakamura H., Toyokuni S., Nakayama Y., et al. Difference in thioredoxin expression in viral myocarditis in inbred strains of mice. Jpn Circ J 2001, 65:561-564.
24. Kishimoto C., Shioji K., Nakamura H., Nakayama Y., Yodoi J., Sasayama S. Serum thioredoxin (TRX) levels in patients with heart failure. Jpn Circ J 2001, 65:491-494.
25. Kishimoto C., Kawamata H., Sakai S., Shinohara H., Ochiai H. Role of MIP-2 in coxsackie virus B3 myocarditis. J Mol Cell Cardiol 2000, 32:631-638.
26. Kondo N., Nomura M., Nakaya Y., Ito S., Ohguro T. Association of inflammatory marker and highly sensitive C-reactive protein with aerobic exercise capacity, maximum oxygen uptake and insulin resistance in healthy middle-aged volunteers. Circ J 2005, 69:452-457.
27. Gielen S., Adams V., Möbius-Winkler S., Linke A., Erbs S., Yu J., et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol 2003, 42:869-872.
28. Milani R.V., Lavie C.J., Mehra M.R. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J Am Coll Cardiol 2004, 43:1056-1061.
29. Yuan Z., Kishimoto C., Sano H., Shioji K., Xu Y., Yokode M. Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion. Am J Physiol 2003, 285:H899-H906.
30. Shioji K., Kishimoto C., Sasayama S. Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis: concomitant suppression of the expression of dendritic cells. Circ Res 2001, 89:540-546.
31. Nicoletti A., Kaveri S., Caligiuri G., Bariéty J., Hansson G.K. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 1998, 102:910-918.
32. Parthasarathy S., Santanam N., Ramachandran S., Meilhac O. Oxidants and antioxidants in atherogenesis: an appraisal. J Lipid Res 1999, 40:2143-2157.
33. Bernal-Mizrachi C., Gates A.C., Weng S., Imamura T., Knutsen R.H., DeSantis P., et al. Vascular respiratory uncoupling increases blood pressure and atherosclerosis. Nature 2005, 435:502-506.
34. Franzoni F., Ghiadoni L., Galetta F., Plantinga Y., Lubrano V., Huang Y., et al. Physical activity, plasma antioxidant capacity, and endothelium-dependent vasodilation in young and older men. Am J Hypertens 2005, 18:510-516.
35. Zhang H., Schmeisser A., Garlichs C.D., Plötze K., Damme U., Mügge A., et al. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH/NADPH-oxidases. Cardiovasc Res 1999, 44:215-222.
36. Sorescu D., Weiss D., Lassègue B., Clempus R.E., Szöcs K., Sorescu G.P., et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002, 105:1429-1435.
37. Cathcart M.K. Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis. Arterioscler Thromb Vasc Biol 2004, 24:23-28.
38. Rajagopalan S., Meng X.P., Ramasamy S., Harrison D.G., Galis Z.S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996, 98:2572-2579.
39. Tsuda M., Iwai M., Li J.M., Li H.S., Min L.J., Ide A., et al. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 2005, 45:545-551.
40. Ni W., Kitamoto S., Ishibashi M., Usui M., Inoue S., Hiasa K., et al. Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 2004, 24:534-539.